Castle Biosciences, Inc.

Castle Biosciences is a company focused on innovative molecular prognostic and diagnostic tests. According to its website, it applies precision genomics to bring sharper answers to diagnosis, treatment, and follow-up, aiming to give care teams and patients confidence to choose the right next step and avoid unnecessary procedures. Its clinical focus areas include dermatology, ophthalmology, and gastroenterology, with tests such as DecisionDx-Melanoma for cutaneous melanoma, tests for atopic dermatitis, cutaneous squamous cell carcinoma, Barrett's esophagus, and uveal melanoma. The company describes itself as an innovator in proprietary laboratory-developed tests that provide personalized, clinically actionable information to help healthcare providers and patients make more informed disease management decisions. Its stated mission is improving health through innovative tests that guide patient care, and its vision is to transform disease management by keeping people first: patients, clinicians, employees and investors. Corporate headquarters are located in Friendswood, Texas, with laboratory and clinical operations in Phoenix, Arizona and Pittsburgh, Pennsylvania.

From the beginning, Castle Biosciences was driven by a desire to help patients receive the best care possible. Its founder believed that traditional methods to determine cancer patients' prognoses could be improved by harnessing the biology of their tumors, and through this belief, Castle was born. The company reports a 2025 milestone: the introduction of AdvanceAD-Tx, involving validation of a neural network algorithm incorporating clinicopathologic factors with the 31-GEP class score for personalized SLNB positivity risk assessment. In 2025, DecisionDx-Melanoma was granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Innovator in proprietary laboratory-developed tests providing personalized, clinically actionable information.

• DecisionDx-Melanoma

  Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma.

• AdvanceAD-Tx

  Introduced in 2025; involves validation of a neural network algorithm incorporating clinicopathologic factors with the 31-GEP class score for personalized SLNB positivity risk assessment.

• Cutaneous Squamous Cell Carcinoma (SCC) test

  Make more confident, more accurate treatment plan decisions for surveillance and therapeutic interventions.

• Barrett's Esophagus test

  Go beyond tissue morphology to predict a patient's individualized risk of progression to esophageal cancer in Barrett's esophagus.

• Uveal Melanoma test

  Make more informed...

• Atopic Dermatitis test

  Guides systemic treatment decision making in patients with moderate-to-severe atopic dermatitis.

1. 1Castle Biosciences | Innovative Molecular Prognostic and Diagnostic Testscastlebiosciences.com
2. 2About Us | Castle Biosciencescastlebiosciences.com
3. 3Careers | Castle Biosciencescastlebiosciences.com
4. 4Contact Us | Castle Biosciencescastlebiosciences.com